<--- Back to Details
First PageDocument Content
Medicine / Drug culture / Addiction / Drug policy / Harm reduction / Public health / Support group / Peer support / Hepatitis C / Ethics / Personal development / Health
Date: 2014-06-27 04:36:55
Medicine
Drug culture
Addiction
Drug policy
Harm reduction
Public health
Support group
Peer support
Hepatitis C
Ethics
Personal development
Health

Add to Reading List

Source URL: www.nuaa.org.au

Download Document from Source Website

File Size: 723,24 KB

Share Document on Facebook

Similar Documents

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

DocID: 1vngt - View Document

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes   

DocID: 1vjI2 - View Document

Contact PD/PI: Braithwaite, Ronald Scott A. SPECIFIC AIMS Many persons with HIV have Hepatitis C (HCV) co-infection and consume alcohol.1,2 Now that highly effective and easily tolerated therapies for HCV are available,

DocID: 1vbzY - View Document

PRESS RELEASE AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection  TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C

DocID: 1vais - View Document